System Governance After CTMS Migration: A Three-Step Plan

Migrating from a legacy clinical trial management system is a major operational change, but the work doesn’t stop when the new platform goes live. Once your teams start working with a new CTMS, the organization will need clear rules for who owns the system, how its performance is reviewed, and what happens when processes need to change. Without this structure, even a well-designed CTMS will gradually become harder to manage. 

In order to stop those well-meaning workarounds and side system spreadsheets, CTMS governance needs to be a part of the migration strategy from day one. A clear governance model gives the organization a practical framework for managing your new platform over time while keeping data, process, and responsibilities consistent. 

Post-migration governance is also an opportunity to establish better working practices from the start. Instead of carrying years of informal process into a new platform, this is your chance to define how the system should be managed going forward. 

But how to hit the ground running? Those first few weeks post-migration are a crucial and busy time. In this installment of our Making the Most series, let’s talk about an easy three-step plan for establishing system governance from the first trials through years to come.

Successful CTMS implementation needs more than technical ownership. There must be a clearly defined CTMS system owner, accountable for the system itself, while business teams remain responsible for the processes and data they use within it. 

This distinction is particularly important after a legacy CTMS migration. In older systems, responsibilities often become blurred over years of incremental changes. User access and reporting control might be owned by different departments, while individual study teams develop their own approaches to data entry or workflow management. 

A new CTMS offers an opportunity to establish those responsibilities clearly and from the start. Organizations should define the role of the CTMS system owner, who will have authority over configuration, user roles, data standards, reporting, integration, and system changes. They should also establish who makes decisions when different groups have competing requirements. 

This isn’t to say that the CTMS system owner is responsible for everything. This role oversees the overall platform and coordinates major changes, while functional owners would remain responsible for the processes in them. These processes include study startup, monitoring, site management, and financial tracking. IT can also manage technical infrastructure and integrations—the CTMS system owner would only take over the responsibility of being the sole decision-maker for business processes. 

Clear ownership gives users a defined path for raising questions or requesting changes. Instead of individual teams creating their own fixes, requests would move through an agreed process with the appropriate stakeholders involved. 

This is especially valuable in large clinical research organizations  where sponsors, CROs, project managers, clinical ops teams, and data teams all interact with the same clinical trial data. A defined governance structure helps keep the system consistent as more studies and users are added. 

Governance doesn’t end after migration. A CTMS audit process gives your team a regular way to check whether the system continues to reflect approved processes and whether users are working with accurate, appropriate data. 

These reviews don’t have to mean a constant stream of formal audits. A practical approach can combine scheduled governance reviews with targeted checks when a significant process, study, or regulatory requirement changes. 

Organizations should review a variety of areas that may have changed since the previous review. These include: 

• User permissions
• Inactive accounts
• Data quality
• Workflow configuration
• Reporting logic
• Integrations
• Changes

Reviewing these areas regularly helps keep small issues from becoming larger operational problems. 

Audits in your clinical trial system governance process should also include a review of how teams actually use the platform. A process that looked like the best option during implementation may no longer fit after a portfolio expands or organizational responsibilities change. Regular reviews give governance teams a chance to identify those patterns and determine whether the underlying CTMS configuration should change. The goal is to assess whether the workflows continue to serve the needs of all clinical trial operations, not only confirm that the system is functioning technically. 

A well-defined CTMS audit trail can also provide useful evidence when reviewing system changes and data activity. Combined with documented ownership and change controls, this creates a useful and quantifiable record of how the platform has been managed over time. 

A CTMS is a living system, not a static piece of software. CROs change, study requirements change, and internal processes change, so CTMS change management needs to account for these shifts. The challenge is in finding the right balance. If every requested change is made immediately, the system becomes inconsistent. If changes are too difficult to request or approve, users tend to create workarounds outside the platform instead of going through the hassle. 

A CTMS change control process gives teams a structured way to assess proposed modifications and act when appropriate. Each request should be evaluated based on its purpose, the users it will affect, impact on existing studies, data implications, reporting requirements, validation needs, and training requirements. Change management should also distinguish between different types of requests. A minor configuration may require a different level of review than a change that affects multiple studies, integrations, permissions, or regulated processes. 

Documentation is another side of change control. Your team must retain a clear record of what changed, why it changed, who approved it, and when it was introduced. This provides useful context when teams review historical study records or investigate unexplained differences in reports. 

Significant changes also demand training. Even a well-designed workflow can create confusion if your users don’t understand what has changed or why the new process exists. Connecting system changes with clear communication helps teams adopt new procedures instead of creating parallel processes. 

The best time to establish CTMS governance best practices is before the migration is complete. This approach gives your organization a clear operating model before users begin creating their own processes around the new system. It also gives system owners a reference point for deciding how future requests should be handled. 

Switching to a modern platform allows teams to establish these practices without carrying every limitation of a legacy system into the next generation of clinical trial operations. With clear ownership and documented governance procedures, your organization will be able to maintain greater consistency across studies while keeping system changes accountable. 

The result is a CTMS that remains governed as the organization grows, rather than gradually becoming another system that requires workarounds. For sponsors, CROs, and academic institutions considering legacy CTMS replacement, that distinction can have a meaningful effect on the long-term value of the migration and the organization itself. 

• Clear CTMS Ownership creates defined responsibility for configuration, users, data, reporting, and system decisions. 
• Regular CTMS audits can identify data, access, reporting, and workflow issues before they become larger operational problems. 
• A documented CTMS change management process gives teams a consistent way to evaluate and approve system modifications. 
• Post-migration CTMS governance helps organizations avoid recreating the workarounds and inconsistencies that often develop around legacy systems. 
• Establishing system governance during CTMS migration  gives teams a stronger foundation for managing the platform as clinical trial operations grow and change.

If you're relying on a CTMS that's been in place for years, it's worth asking a simple question: is it helping your teams make decisions faster, or just recording what's already happened?

At BSI Life Sciences, we work with enterprise sponsors looking to modernize their clinical operations without disrupting ongoing studies. If you'd like to explore what's possible, let’s start the conversation!